While PD-L1 expression is often used as a biomarker for response to PD-1/PD-L1 inhibitors, its predictive value in CRC is inconsistent because of the tumor heterogeneity, complex interplay between tumor cells and immune cells expressing PD-L1, and technical variability in sample staining [71,73]. Here, CD274 is linked to neoplasm.